In IDH1 (the cytosolic NADP-dependent isoform), almost all gliomas are associated with an active site R132H mutation [45], whereas in IDH2 (the mitochondrial NAD-dependent homolog), the main active site mutation is R172K [44]. Here, IDH2 is linked to central nervous system cancer.